Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Webcasts
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    Advanced Search
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Canadian Federal Government
        • Canadian Municipal Government
        • Canadian Provincial Government
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Advanced Search
    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • IR
    • All Products
    • Become a Client
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • General Enquiries
    • Media
    • Worldwide Offices
    • Hamburger menu
    • Cision Canada
    • Send a Release
    • FR
      • Phone

      • 877-269-7890 from 8 AM - 10 PM ET

      • ALL CONTACT INFO
      • Contact Cision

        877-269-7890
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • 3 News in Focus
      • 5 Business
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • IR
      • All Products
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media
      • Worldwide Offices
      • General Enquiries
      • Send a Release
      • Sign Up
      • Resources
      • Investor Relations
      • Journalists
      • Webcasts
      • my CNW
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business) Business
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cipher Reports Q1 2012 Financial Results


      News provided by

      Cipher Pharmaceuticals Inc.

      May 04, 2012, 07:00 ET

      Share this article

      Share this article


      Toronto Stock Exchange Symbol: DND

      MISSISSAUGA, ON, May 4, 2012 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND; OTC: CPHMF.PK) today announced its financial and operational results for the three months ended March 31, 2012 ("Q1 2012").

      Q1 2012 Summary

      • Achieved quarterly revenue of $1.8 million, a 168% increase over Q1 2011.
      • Net income in Q1 2012 was $0.1 million, compared with a loss of $1.1 million in Q1 2011.
      • Received a US$1.0 million sales milestone for Lipofen®.
      • Durela™ (extended-release tramadol) was launched in March 2012 by Cipher's Canadian partner, Medical Futures Inc.
      • Cash increased for the third consecutive quarter to $10.1 million, compared with $9.6 million as at December 31, 2011.

      "Revenue grew strongly in the first quarter based on Lipofen's performance and early contributions from ConZipä, which was recently launched in the U.S.," said Larry Andrews, President and CEO of Cipher. "In addition, with the launch of Durelaä in Canada, we now have multiple royalty revenue streams contributing to our results as we await U.S. regulatory approval for CIP-ISOTRETINOIN, our promising product for the treatment of acne."

      Financial Review

      Net revenue in Q1 2012 was $1.8 million, an increase of 168% compared with $0.7 million in Q1 2011. Revenue from Lipofen® increased to $1.4 million during Q1 2012 compared with $0.6 million in Q1 2011, reflecting a strong performance by our U.S. partner, Kowa Pharmaceuticals, and the achievement of a contractual net sales milestone, which contributed $0.5 million in revenue for the quarter.  Revenue from ConZipä was $0.3 million in Q1 2012.  No revenue was recognized in Q1 of the prior year as the product was launched in Q3 2011. Revenue from Durelaä was not significant during Q1 2012 as the product was only launched in mid-March 2012.

      Research and Development expense during Q1 2012 was $0.5 million, the same as incurred in Q1 2011. Operating, General and Administrative expenses for Q1 2012 declined to $1.0 million, compared to $1.2 million in Q1 2011. Net income in Q1 2012 was $0.1 million, or $0.01 per share, compared to a net loss of $1.1 million, or $0.05 per share, in Q1 2011.

      The Company's financial position remained solid at quarter end. As at March 31, 2012, Cipher had cash of $10.1 million, compared with $9.6 million as at December 31, 2011.

      Product Update

      Lipofen®
      During Q1 2012, Lipofen® monthly prescriptions increased solidly relative to the prior quarter based on Kowa's increased promotional effort and a new managed care client contract. Lipofen® achieved record sales performance for the quarter, with royalty revenue 65% higher than the prior year and 26% higher than Q4 2011. During the first quarter, Cipher received a US$1.0 million milestone payment from Kowa. Cipher's 50% share of the milestone is reflected in its financial results for Q1 2012. This one-time milestone, which was based on sales performance over the trailing 12-month period, reflected steadily increasing new prescriptions during the fourth quarter and Q1 2012.

      CIP-TRAMADOL ER (ConZip™/Durela™)
      Cipher's extended-release tramadol was launched in the U.S. by Vertical Pharmaceuticals in September 2011 under the trade name ConZip™. Vertical's dedicated sales force comprises 60 representatives, with plans for further expansion in 2012.  Product sales to date have been encouraging and the Company expects solid growth in 2012 as U.S. physicians gain more experience with the product and Vertical expands its coverage.

      During Q3 2011, Cipher received Health Canada approval for CIP-TRAMADOL ER and also completed a Canadian distribution and supply agreement with Medical Futures. Medical Futures launched the product in March 2012 under the trade name Durela™, with a dedicated sales force comprising approximately 22 representatives.

      CIP-ISOTRETINOIN
      Cipher's New Drug Application for CIP-ISOTRETINOIN is currently under review by the FDA with a target action date under PDUFA of May 29, 2012.  Pre-commercial activities are underway with Ranbaxy Pharmaceuticals, the Company's U.S. partner, for a possible launch in Q4 2012. When CIP-ISOTRETINOIN is commercialized, Cipher expects that it will have the potential to generate significant revenue for the Company.

      Cipher completed a New Drug Submission to Health Canada in Q4 2011.  This was accepted for review in Q1 2012, and a response from Health Canada is expected in Q1 2013.  Once approved, Cipher plans to market the product in Canada on its own.

      New Products and Out-Licensing Activities
      Cipher is actively pursuing out-licensing discussions for its current products in other territories and is seeking late to commercial stage product candidates to complement its Canadian commercialization plans for CIP-ISOTRETINOIN.

      Notice of Conference Call

      Cipher will hold a conference call today, May 4, 2012, at 8:30 a.m (ET) to discuss its financial results and other corporate developments. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191.  A live audio webcast of the call will be available at www.cipherpharma.com. The webcast will be archived for 90 days.

      About Cipher Pharmaceuticals Inc.

      Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF.PK) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules.  Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners.  The Company's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip™ and is marketed in Canada as Durela™.  Cipher's New Drug Application for its third product, a novel formulation of the acne treatment isotretinoin, is currently being reviewed by the FDA and Health Canada. For more information, please visit www.cipherpharma.com.

      Forward-Looking Statements

      Statements made in this news release, other than those concerning historical financial information, may be forward-looking and therefore subject to various risks and uncertainties. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.  Factors that could cause results to vary include those identified in the Company's Annual Information Form and other filings with Canadian securities regulatory authorities. These factors include, but are not limited to losses; the applicability of patents and proprietary technology; possible patent litigation; approval of products in the Company's pipeline; marketing of products; meeting projected drug development timelines and goals; product liability and insurance; dependence on strategic partnerships and licensees; concentration of the Company's revenue; substantial competition and rapid technological change in the pharmaceutical industry; the publication of negative results of clinical trials of the Company's products; the ability to access capital; the ability to attract and retain key personnel; changes in government regulation or regulatory approval processes; dependence on contract research organizations; third party reimbursement; the success of the Company's strategic investments; the achievement of development goals and time frames; the possibility of shareholder dilution; market price volatility of securities; and the existence of significant shareholders. All forward-looking statements presented herein should be considered in conjunction with such filings. Except as required by Canadian securities laws, the Company does not undertake to update any forward-looking statements; such statements speak only as of the date made.

      Cipher Pharmaceuticals Inc.      
      Balance Sheets      
             
      As at March 31, 2012 and December 31, 2011      
      (in thousands of Canadian dollars - unaudited)    
             
        March 31,   December 31,
        2012   2011
        $   $
      ASSETS      
             
      Current assets      
        Cash 10,113   9,636
        Accounts receivable 1,937   1,782
        Prepaid expenses and other assets 180   272
        12,230   11,690
             
        Property and equipment, net 28   25
             
        Intangible assets, net 2,719   2,944
             
        14,977   14,659
             
      LIABILITIES      
             
      Current liabilities      
        Accounts payable and accrued liabilities 2,212   1,912
        Current portion of deferred revenue 875   917
        3,087   2,829
             
        Deferred revenue 2,177   2,330
        5,264   5,159
             
      SHAREHOLDERS' EQUITY      
             
        Share capital 50,211   50,172
        Contributed surplus 33,081   33,032
        Deficit (73,579)   (73,704)
        9,713   9,500
             
        14,977   14,659
      Cipher Pharmaceuticals Inc.      
      Statements of Operations and Comprehensive Income (Loss)    
             
      Three month periods ended March 31, 2012 and 2011    
      (in thousands of Canadian dollars, except per share data - unaudited)
           
        March 31,   March 31,
        2012   2011
        $   $
             
      Revenues      
        Licensing revenue 1,811   675
             
      Expenses      
        Research and development 471   547
        Operating, general and administrative 1,016   1,177
        Amortization of intangible assets 225   59
        Interest income (26)   (23)
             
        1,686   1,760
             
             
      Income (loss) and comprehensive income (loss) for the period 125   (1,085)
             
             
      Basic and diluted earnings (loss) per share 0.01   (0.05)


      Cipher Pharmaceuticals Inc.
                   
      Statements of Changes in Equity              
                     
      Three month periods ended March 31, 2012 and 2011            
      (in thousands of Canadian dollars - unaudited)              
                     
                    Total
        Share   Contributed       Shareholders'
        Capital   Surplus   Deficit   Equity
        $   $   $   $
                     
      Balance, January 1, 2012 50,172   33,032   (73,704)   9,500
                     
      Income and comprehensive income for the period -   -   125   125
                     
      Shares issued under the share purchase plan 39   -   -   39
                     
      Share-based compensation - stock option plan -   49   -   49
                     
      Balance, March 31, 2012 50,211   33,081   (73,579)   9,713
                     
      Balance, January 1, 2011 49,977   32,890   (71,393)   11,474
                     
      Loss and comprehensive loss for the period -   -   (1,085)   (1,085)
                     
      Share-based compensation - stock option plan -   28   -   28
                     
      Balance, March 31, 2011 49,977   32,918   (72,478)   10,417
      Cipher Pharmaceuticals Inc.      
      Statements of Cash Flows      
             
      Three month periods ended March 31, 2012 and 2011      
      (in thousands of Canadian dollars - unaudited)       
             
        March 31,   March 31,
        2012   2011
        $   $
      Cash provided by (used in)      
             
      Operating activities      
        Income (loss) for the period 125   (1,085)
        Items not affecting cash:      
          Depreciation of property and equipment 7   13
          Amortization of intangible assets 225   59
          Share-based compensation - share purchase plan 6   -
          Share-based compensation - stock option plan 49   28
        412   (985)
             
        Changes in non-cash operating items:      
          Accounts receivable (155)   216
          Prepaid expenses and other assets 92   100
          Accounts payable and accrued liabilities 300   (364)
          Deferred revenue (195)   (144)
             
      Net cash generated from (used in) operating activities  454   (1,177)
             
      Investing activities      
        Purchase of property and equipment (10)   (4)
             
      Net cash generated from (used in) investing activities  (10)   (4)
             
      Financing activities      
        Proceeds from shares issued under the share purchase plan 33   -
             
      Increase (Decrease) in cash 477   (1,181)
      Cash, beginning of period 9,636   10,328
             
      Cash, end of period 10,113   9,147

      Craig Armitage
      Investor Relations
      The Equicom Group
      (416) 815-0700 ext 278
      (416) 815-0080 fax
      [email protected]

      Larry Andrews
      President and CEO
      Cipher Pharmaceuticals
      (905) 602-5840 ext 324
      (905) 602-0628 fax
      [email protected]

      Modal title

      Organization Profile

      Cipher Pharmaceuticals Inc.

        Also from this source

      • Cipher Pharmaceuticals Reports Third Quarter 2026 Results

      • Cipher Pharmaceuticals Schedules Q3 2026 Earnings Release and Conference Call

      • Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors

      Contact PR Newswire

      • 866-245-2317
        from 7:30 AM - 6:30 PM ET
      • Become a Client
      • Request a Demo
      • Editorial Bureaus
      • Partnerships
      • General Enquiries
      • Media

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • Investor Relations

      About

      • About PR Newswire
      • About Cision
      • Careers
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • Platform Login
      • Privacy Policy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      • Next Gen Communications Cloud
      • Cision Communications Cloud
      • my CNW
      877-269-7890
      from 8 AM - 10 PM ET
      • Terms of Use
      • Information Security Policy
      • Site Map
      • Cookie Settings
      • Accessibility Statement
      Copyright © 2026 CNW Group Ltd. All Rights Reserved. A Cision company.